Last 31.70 TWD
Change Today -0.70 / -2.16%
Volume 1.7M
4142 On Other Exchanges
Symbol
Exchange
Taiwan
As of 2:38 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

adimmune corp (4142) Snapshot

Open
32.40
Previous Close
32.40
Day High
32.50
Day Low
31.60
52 Week High
01/21/14 - 49.80
52 Week Low
08/28/14 - 30.05
Market Cap
7.5B
Average Volume 10 Days
1.4M
EPS TTM
-3.25
Shares Outstanding
237.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADIMMUNE CORP (4142)

Related News

No related news articles were found.

adimmune corp (4142) Related Businessweek News

No Related Businessweek News Found

adimmune corp (4142) Details

Adimmune Corporation develops, manufactures, and distributes human vaccines in Taiwan. The company’s primary products include AdimFlu-s (AH1N1), Japanese encephalitis vaccine, and tetanus toxoid alum precipitated, as well as influenza vaccine. It also provides fill and finish services; product testing and analysis of quality of vaccines and biological products, as well as other relevant tests; quality assurance courses, comprising introductory courses on GMP-related subjects to schools and industries; and consulting services, such as planning, design, construction, validation, and project management of biological product plant. In addition, the company rents cold storage facilities; and distributes Tuberculin PPD product. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is based in Taichung, Taiwan.

Founded in 1965

adimmune corp (4142) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

adimmune corp (4142) Key Developments

Adimmune Corporation, Annual General Meeting, Jun 19, 2014

Adimmune Corporation, Annual General Meeting, Jun 19, 2014.

Adimmune Corporation - Shareholder/Analyst Call

To illustrative overview

Adimmune Begins Phase III Trial of Flu Vaccine Ahead of 2014 Launch in China

Adimmune has announced receipt of approval from the Chinese Food and Drug Administration to begin Phase III trials of a flu vaccine, with the expectation to launch on the market during the first half of 2014. The firm states that development of the drug benefited from the Cross-Strait Cooperation Agreement on Medicine and Public Health Affairs between China and Taiwan, meaning that Phase III approval took 3 years rather than the 5 to 6 years required for other companies. The firm also gave price and sales volume expectations, stating it will produce vaccines in 0.5cc and 0.25cc vials, priced at an average of around CNY 50 or CNY 60 (USD 8.16/USD 9.79). Sales are expected to be less than 1 million vials during 2014, increasing to 3 million-5 million by 2016 and accounting for around a 10% market share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4142:TT 31.70 TWD -0.70

4142 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4142.
View Industry Companies
 

Industry Analysis

4142

Industry Average

Valuation 4142 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.0x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADIMMUNE CORP, please visit www.adimmune.com.tw. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.